NAION & Ozempic Lawsuit News & Updates
Sudden vision loss after GLP-1 injections is a narrow allegation set inside the brand-new MDL 3163 in Philadelphia. This hub foregrounds NAION charting, prescribing intervals, and ophthalmology records reviewers care about—not generic drug-injury language.
Last updated: May 13, 2026
NAION / Ozempic Litigation at a Glance
No. 3163 (E.D. Pa.)
Hon. Karen S. Marston
Growing (federal + state)
Discovery and bellwether planning ongoing
Latest NAION / Ozempic Lawsuit Update
Early GLP-1 vision cases borrow mass-tort logistics but hinge on optic-nerve findings within tight post-injection windows. MDL 3163 will test whether NAION incidence data, FDA correspondence, and prescriber warnings belong in the same discovery pool.
Current NAION / Ozempic Lawsuit News
- •Federal NAION/GLP-1 vision loss cases centralized in MDL 3163, In re: GLP-1 RA Products Liability Litigation (No. II), Eastern District of Pennsylvania
- •MDL created December 2025; Judge Karen S. Marston presiding
- •Plaintiffs allege Novo Nordisk and Eli Lilly failed to warn about NAION (vision loss) risk with Ozempic, Wegovy, Mounjaro, Zepbound, and related drugs
- •EMA added NAION as a very rare side effect for semaglutide (June 2025); FDA label update pending in the U.S.
- •Additional cases filed in state court, including New Jersey; litigation in early stages
Legal Case Updates: MDL and NAION / GLP-1 Litigation
NAION/GLP-1 litigation is centralized in In re: GLP-1 RA Products Liability Litigation (No. II), MDL No. 3163, in the Eastern District of Pennsylvania before Judge Karen S. Marston. The MDL was created in December 2025. This consolidation streamlines discovery, bellwether selection, and rulings on common legal and scientific issues. Plaintiffs allege that Novo Nordisk and Eli Lilly knew or should have known about the risk of NAION (vision loss) with Ozempic, Wegovy, Mounjaro, Zepbound, and related GLP-1 drugs and failed to adequately warn patients and doctors.
Why This Isn't a Class Action
An MDL is different from a class action. In a class action, one outcome would apply to the whole group. In the MDL, each plaintiff keeps an individual case and any settlement or verdict is based on that person's injuries and damages. This structure typically allows for higher compensation for those with more severe harm.
Key Dates and Legal Developments
| Date / Period | Development |
|---|---|
| July 2024 | JAMA Ophthalmology study finds significantly elevated NAION risk with semaglutide (4.28x–7.64x). |
| June 2025 | European Medicines Agency adds NAION as a "very rare" side effect for semaglutide-containing medicines. |
| December 2025 | Judicial Panel on Multidistrict Litigation creates MDL No. 3163 (E.D. Pa.) for GLP-1 NAION vision loss cases; Judge Karen S. Marston assigned. |
| 2026 | Discovery and bellwether planning ongoing. Additional cases filed in federal and state court. |
Science & Evidence Behind the Claims
Peer-reviewed research has raised concerns about an association between GLP-1 receptor agonists (e.g., semaglutide) and NAION. Plaintiffs allege that manufacturers knew or should have known of this risk and failed to warn. Key developments include:
JAMA Ophthalmology (July 2024)
European Medicines Agency (June 2025)
Think You May Qualify?
If you took Ozempic, Wegovy, or another GLP-1 drug and were diagnosed with NAION or sudden vision loss, you may be eligible for a free case review. Get the full picture on eligibility, settlement estimates, and how to get connected with a law firm.
NAION & Ozempic Lawsuit – Free Case ReviewFrequently Asked Questions
Ready to See If You Qualify?
Free, confidential case review. No obligation. We may connect you with an independent law firm if appropriate.
Start Free Case ReviewDisclaimer
This NAION / Ozempic lawsuit news page is for informational purposes only and does not constitute legal advice. Top Tier Legal LLC is not a law firm. Litigation status and dates may change. For the most current update and to see if you qualify for a free case review, visit our NAION & Ozempic lawsuit page or contact us.